Abstract
Successful prevention and treatment of late-onset Alzheimer‘s disease (AD) is a high priority for industrialized societies where the incidence is growing rapidly. Much of the underlying biology leading to AD is unknown, and the more knowledge we gain the more we appreciate the complexities involved. Popular etiologic hypotheses have largely ignored the blood–brain barrier (BBB) as an important factor contributing to the pathologic hallmarks of this most common form of dementia. Evidence identifying BBB dysfunction in AD or patients at risk (i.e., those with mild cognitive impairment) continue to escalate. This review highlights methodological issues facing investigators assessing BBB integrity in living patients while also discussing whether the BBB dysfunction is a cause, effect or epiphenomenon in AD. Rationale for future research pursuits aimed at describing the role of BBB function in AD pathogenesis is also presented.
Financial & competing interests disclosure
Gene L Bowman has recieved the NCCAM T32 AT002688 Ruth L Kirschstein National Research Service Award (GLB), NIA AG08017.
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.